Advertisement

C-Reactive Protein: A Clinical Marker in Cardiovascular Disease

  • Waliza Ansar
  • Shyamasree Ghosh
Chapter

Abstract

Atherosclerotic vascular disease reveals the process of inflammation including several key mediators and markers of inflammation as major manifestations of its pathobiology. Different inflammation markers observed in atherosclerotic disease have been implicated for their prediction of risk in vascular disease or vascular events. Among them, extensively studied is C-reactive protein (CRP), a protein categorized under the class of acute-phase response (APR) proteins. CRP has been reported for its most consistent relationship with cardiovascular disease (CVD) and is capable of predicting risk in the future. Recent epidemiological studies in population have confirmed positive associations between CRP and CVD in populations across the globe. The role of CRP in binding with lipoprotein and activation of the complement cascade reactions and its localization in atherosclerotic vessels indicate strongly the involvement of CRP in the pathophysiology of heart diseases. Initially identified for its major role as a marker in acute processes like tissue injury, infection by pathogen, and inflammation, recently it has earned the disease biomarker status in different CVDs. The role of hs-CRP in detection of risk of cardiovascular diseases is highly accomplished. Use of hs-CRP has well-known clinical and pathological significance. Among hundreds of putative cardiovascular risk factors together with factors including behavioral, biochemical, environmental, and genetic risk markers, CRP remains a unique risk predictor globally. The future prospect of C-reactive protein as a disease biomarker in CVD will help add to the knowledge of the pathobiology and to follow-up studies in patients suffering from CVDs.

Keywords

Cardiovascular diseases (CVDs) C-reactive protein Cardiovascular risk factors Atherosclerosis Inflammation hs-CRP 

References

  1. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 105:2595–2599CrossRefPubMedGoogle Scholar
  2. Al-Waili NS (2004) Natural honey lowers plasma glucose, C-reactive protein, homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with dextrose and sucrose. J Med Food 7:100e7Google Scholar
  3. Amrock SM, Weitzman M (2014) Effect of increased leptin and C-reactive protein levels on mortality: results from the National Health and Nutrition Examination Survey. Atherosclerosis 236(1):1–6. doi: 10.1016/j.atherosclerosis.2014.06.009. Epub 2014 Jun 23CrossRefPubMedPubMedCentralGoogle Scholar
  4. Biasucci LM, Liuzzo G, Fantuzzi G et al (1999) Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalisation in unstable angina are associated with increased risk of in hospital coronary events. Circulation 99:2079–2084CrossRefPubMedGoogle Scholar
  5. Blake JG, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 98:763–771CrossRefGoogle Scholar
  6. Boras E, Slevin M, Alexander MY, Aljohi A, Gilmore W, Ashworth J, Krupinski J, Potempa LA, Al Abdulkareem I, Elobeid A, Matou-Nasri S (2014) Monomeric C-reactive protein and Notch-3 co-operatively increase angiogenesis through PI3K signalling pathway. Cytokine 69(2):165–179. doi: 10.1016/j.cyto.2014.05.027. Epub 2014 Jun 25CrossRefPubMedGoogle Scholar
  7. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M (2009) C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med 151:483e95CrossRefGoogle Scholar
  8. Castelli WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124(Suppl):S1–S9CrossRefPubMedGoogle Scholar
  9. Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17:1019–1025CrossRefPubMedGoogle Scholar
  10. Creactive Protein Coronary Heart Disease Genetics Collaboration (CCGC), Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, Engert JC, Clarke R, Davey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L,Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J (2011) Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 342:d548. doi: 10.1136/bmj.d548
  11. Cybulsky MI, Gimbrone MA (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788–791CrossRefPubMedGoogle Scholar
  12. Danesh J, Pepys MB (2009) C-reactive protein and coronary disease: is there a causal link? Circulation 120:2036–2039CrossRefPubMedGoogle Scholar
  13. Das T, Sen A, Kempf T, Pramanik SR, Mandal C, Mandal C (2003) Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J 373(Pt 2):345–355CrossRefPubMedPubMedCentralGoogle Scholar
  14. Davies MJ (1996) Stability and instability: two faces of coronary atherosclerosis. Circulation 94:2013–2020CrossRefPubMedGoogle Scholar
  15. De Beer FC, Pepys MB (1982) Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods 50:17–31CrossRefPubMedGoogle Scholar
  16. De Beer FC, Dyck RF, Pepys MB (1982a) Solid-phase immunoradiometric assay for serum amyloid A protein using magnetisable cellulose particles. J Immunol Methods 54(2):213–221Google Scholar
  17. De Beer FC, Shine B, Pepys MB (1982b) Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol 50(1):231–237Google Scholar
  18. de Ferranti S, Rifai N (2002) C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 317:1–15CrossRefPubMedGoogle Scholar
  19. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundström J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D’Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gómez-de-la-Cámara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J (2012) Lipid-related markers and cardiovascular disease prediction. JAMA 307(23):2499–2506. doi: 10.1001/jama.2012.6571 Google Scholar
  20. Farzaneh-Far AF, Rudd J, Weissberg PL (2001) Myocardial ischemia: inflammatory mechanisms. Br Med Bull 59:55–68CrossRefPubMedGoogle Scholar
  21. Ganie MA, Hassan S, Nisar S, Shamas N, Rashid A, Ahmed I, Douhat S, Mudassar S, Jan VM, Rashid F (2014) High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 30(11):781–784. doi: 10.3109/09513590.2014.924099. Epub 2014 Aug 19CrossRefPubMedGoogle Scholar
  22. Gomes MC (2002) C-reactive protein: a new golden marker of cardiovascular risk. Rev Port Cardiol 21(11):1329–1346PubMedGoogle Scholar
  23. Gonzalez-Amaro R, Diaz-Gonzalez F, Sánchez- Madrid F (1998) Adhesion molecules in inflammatory diseases. Drugs 56:977–988CrossRefPubMedGoogle Scholar
  24. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T et al (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 190:1733–1739CrossRefPubMedPubMedCentralGoogle Scholar
  25. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 349:462–466CrossRefPubMedGoogle Scholar
  26. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636CrossRefPubMedPubMedCentralGoogle Scholar
  27. Hu FB (2008) Globalization of food patterns and cardiovascular disease risk. Circulation 118(19):1913–1914CrossRefPubMedGoogle Scholar
  28. Jarczok MN, Koenig J, Mauss D, Fischer JE, Thayer JF (2014) Lower heart rate variability predicts increased level of C-reactive protein 4 years later in healthy, nonsmoking adults. J Intern Med 276(6):667–671. doi: 10.1111/joim.12295. Epub 2014 Sep 8CrossRefPubMedGoogle Scholar
  29. Krishnaswamy G, Smith JK, Mukkamala R et al (1998) Multifunctional cytokine expression by human coronary endothelium and glycocorticoids. Microvasc Res 55:189–200CrossRefPubMedGoogle Scholar
  30. Kushner I (2002) C-reactive protein and atherosclerosis. Science 297:520–521CrossRefPubMedGoogle Scholar
  31. Kushner I, Kaplan MH (1967) Antigenic analysis of extracts of human heart tissue: cardiac antigens with limited distribution in other organs. J Immunol 99:526–533PubMedGoogle Scholar
  32. Kushner I, Rakita L, Kaplan MH (1963) Studies of acute phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest 42:286–292CrossRefPubMedPubMedCentralGoogle Scholar
  33. Ladue TB, Weiner DL, Sipe J et al (1997) Analytical evaluation of particle-enhanced immunonephelometric assay for C-reactive protein, serum amyloid A, and mannose-binding protein in human serum (abs). Clin Chem 43:S240Google Scholar
  34. Lee Y, Kang D, Lee S-A (2014) Effect of dietary patterns on serum C-reactive protein level. Nutr Metab Cardiovasc Dis 24(9):1004–1011CrossRefPubMedGoogle Scholar
  35. Li X, Chen C, Gan F, Wang Y, Ding L, Hua W (2014) Plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc Disord 14:67. doi: 10.1186/1471-2261-14-67 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91:2844–2850CrossRefPubMedGoogle Scholar
  37. Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424CrossRefPubMedGoogle Scholar
  38. Lloyd-Jones DM, Liu K, Lu T, Greenland P (2006) Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 145:35–42CrossRefPubMedGoogle Scholar
  39. Macy EM, Hayes TE, Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological application. Clin Chem 43:52–58PubMedGoogle Scholar
  40. Marcucci R, Valente S, Gori AM, Chiostri M, Paniccia R, Giusti B, Cau V, Lazzeri C, Gensini GF, Abbate R (2014) Global platelet hyperreactivity and elevated C-reactive protein levels predict long term mortality in STEMI patients. Thromb Res 134(4):884–888. doi: 10.1016/j.thromres.2014.07.020. Epub 2014 Jul 24CrossRefPubMedGoogle Scholar
  41. Markowicz S, Delforge M, Necsoi C, De Wit S (2014) Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations. J Int AIDS Soc 17(4 Suppl 3):19515. doi: 10.7448/IAS.17.4.19515. eCollection 2014PubMedPubMedCentralGoogle Scholar
  42. Morrow DA, Rifai N, Antman L (2000) Serum amyloid-A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 35:358–363CrossRefPubMedGoogle Scholar
  43. Obradovic MM, Trpkovic A, Bajic V, Soskic S, Jovanovic A, Stanimirovic J, Panic M, Isenovic ER (2015) Interrelatedness between C-reactive protein and oxidized low-density lipoprotein. Clin Chem Lab Med 53(1):29–34. doi: 10.1515/cclm-2014-0590 CrossRefPubMedGoogle Scholar
  44. Olson RE (2000) Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr 47:55–78PubMedGoogle Scholar
  45. Patel BV, Robbins MA, Topol EJ (2001) C-reactive protein: a “golden marker” for inflammation and coronary artery disease. Cleve Clin J Med 68:521–534CrossRefPubMedGoogle Scholar
  46. Pepys MB (1996) The acute phase response and C reactive protein. In: Weartherall DJ, Ledingham JGG, Warrel DA (eds) Oxford textbook of medicine, 3rd edn. Oxford University Press, Oxford, pp 1527–1533Google Scholar
  47. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805–1812CrossRefPubMedPubMedCentralGoogle Scholar
  48. Pereira IA, Borba EF (2008) The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly 138:534–539PubMedGoogle Scholar
  49. Pfützner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8(1):28–36CrossRefPubMedGoogle Scholar
  50. Pietilla KO, Harmoinen AP, Jokiniitty J, Pastemack AI (1996) Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17:1345–1349CrossRefGoogle Scholar
  51. Price DT, Loscalzo J (1999) Cellular adhesion molecules and atherogenesis. Am J Med 107:85–97CrossRefPubMedGoogle Scholar
  52. Ridker PM (1999) Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 130:933–939CrossRefPubMedGoogle Scholar
  53. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818CrossRefPubMedGoogle Scholar
  54. Ridker PM (2003) Mini-review: expert opinions, clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363–369CrossRefPubMedGoogle Scholar
  55. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230–235CrossRefPubMedGoogle Scholar
  56. Ridker PM, Rifai N, Pfeffer M et al (2000) Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation 101:2149–2154CrossRefPubMedGoogle Scholar
  57. Ridker PM, Stampfer MJ, Rifai N (2001a) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285(19):2481–2485CrossRefPubMedGoogle Scholar
  58. Ridker PM, Rifai N, Lowenthal SP (2001b) Rapid reduction of C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191–1193CrossRefPubMedGoogle Scholar
  59. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS et al (2001c) Measurement of C-reactive protein for the targeting of stain therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959–1965CrossRefPubMedGoogle Scholar
  60. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators (2001d) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344(26):1959–1965CrossRefPubMedGoogle Scholar
  61. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, for the Jupiter Study Group et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C – reactive protein. N Engl J Med 359:2195–2207CrossRefPubMedGoogle Scholar
  62. Ristisch K (2002) The race to develop tools to pinpoint arterial inflammation. HeartwireGoogle Scholar
  63. Ross R (1976) The pathogenesis of atherosclerosis. N Engl J Med 295(369–77):420–425CrossRefPubMedGoogle Scholar
  64. Ross R (1999) Atherosclerosis – an inflammatory disease. N Engl J Med 340:123–135Google Scholar
  65. Rus HG, Vlaicu R, Niculescu F (1996) Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127:263–271CrossRefPubMedGoogle Scholar
  66. Sung KC, Rhee EJ, Kim H, Park JB, Kim YK, Rosenson RS (2012) Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults. Nutr Metab Cardiovasc Dis 22:1061e6CrossRefGoogle Scholar
  67. Takahashi H, Iinuma S, Honma M, Iizuka H (2014) Increased serum C-reactive protein level in Japanese patients of psoriasis with cardio- and cerebrovascular disease. J Dermatol 41(11):981–985. doi: 10.1111/1346-8138.12632. Epub 2014 Oct 8PubMedGoogle Scholar
  68. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635–641CrossRefPubMedGoogle Scholar
  69. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ (1992) Mechanisms in intimal monocytes-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 86:III-20–III-25Google Scholar
  70. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A (1991) Expression of monocyte chemotactic protein-1 and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 11(5):1166–1174CrossRefPubMedGoogle Scholar
  71. Westhorpe CL, Schneider HG, Dunne M, Middleton T, Sundararajan V, Spelman T, Carter V, Crowe SM, Dart A, Mijch A, Kotsanas D, Woolley I (2014) C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sex Health 11(6):580–582. doi: 10.1071/SH14130 CrossRefPubMedGoogle Scholar
  72. Yeh ET, Willerson JT (2003) Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107:370–372CrossRefPubMedGoogle Scholar
  73. Yeh ET, Anderson HV, Pasceri V, Willerson JT (2001) C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104:974–975CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Waliza Ansar
    • 1
  • Shyamasree Ghosh
    • 2
  1. 1.Department of ZoologyBehala CollegeKolkataIndia
  2. 2.National Institute of Science EducationSchool of Biological SciencesBhubaneswarIndia

Personalised recommendations